This report presents the outcomes of exerting extracted Salvadora persica for synthesizing ZnO nanoparticles (ZnO−NP) and Mn‐doped ZnO nanorods (Mn−ZnO−NRs) through a viable and economical “green” route. The products characteristics were configured by the means of X‐ray diffraction (XRD), field emission scanning electron microscopy (FESEM), energy‐dispersive X‐ray (EDX) spectroscopy, UV‐visible spectroscopy (UV‐Vis) and Raman assessing technics. As the constructional evaluations approved the progress of well crystalline nano, the EDX analyses approved the doping of Mn, which interestingly succeeded in significantly altering the spherical framework of ZnO into a rod‐looking structure. The following steps involved the employment of MTT trial to assay the cytotoxic impacts of our sample towards breast (MCF‐7: Michigan Cancer Foundation‐7) cancer cell line, resulting in confirming the superior outcomes of Mn−ZnO−NRs than the solitary case of ZnO. The boosted functionality of the doped product may be attributable to the appearance of Mn into the lattice of ZnO. In addition, the evolved morphology of ZnO, obtained through the doping process, could have caused substantial developments in the cytotoxic operation of doped sample as well.
Hepatitis C virus (HCV) is a major cause of end-stage liver diseases like cirrhosis and hepatocarcinoma, posing a serious worldwide threat when left untreated. Nowadays, direct-acting antivirals (DAAs) constitute core components of anti-HCV treatment. Nonetheless, some DAAs are associated with a growing level of drug resistance as well as adverse reactions. That is why introducing new anti-HCV drugs with higher potency and lower toxicity is so essential. NS5B polymerase is an HCV non-structural protein that acts as a critical target for the development of anti-HCV therapeutics. Based on the necessary pharmacophores for inhibition of HCV NS5B polymerase, a novel series of phthalamide analogs that harbor the potential of NS5B polymerase inhibition to stop HCV proliferation in a cell-based assay were designed, synthesized, and in-vitro evaluated. Interestingly, all compounds displayed low cellular cytotoxicity in Huh 7.5 cells (CC 50 > 100). Compound 28 with EC 50 of 6.0 µM, and an appropriate affinity to NS5B polymerase active site could be considered as a new hit compound, providing useful information for the design of novel HCV inhibitors.
Hepatitis C virus (HCV) is a major cause of end-stage liver diseases like cirrhosis and hepatocarcinoma, posing a serious worldwide threat when left untreated. Nowadays, direct-acting antivirals (DAAs) constitute core components of anti-HCV treatment. Nonetheless, some DAAs are associated with a growing level of drug resistance as well as adverse reactions. That is why introducing new anti-HCV drugs with higher potency and lower toxicity is so essential. NS5B polymerase is an HCV non-structural protein that acts as a critical target for the development of anti-HCV therapeutics. Based on the necessary pharmacophores for inhibition of HCV NS5B polymerase, a novel series of phthalamide analogs that harbor the potential of NS5B polymerase inhibition to stop HCV proliferation in a cell-based assay were designed, synthesized, and in-vitro evaluated. Interestingly, all compounds displayed low cellular cytotoxicity in Huh 7.5 cells (CC 50 > 100). Compound 28 with EC 50 of 6.0 µM, and an appropriate a nity to NS5B polymerase active site could be considered as a new hit compound, providing useful information for the design of novel HCV inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.